Key facts
- Epana Bio’s last known valuation is $27.0M (Mar 2025).
- It has raised $14.0M; the latest was Seed Round ($11.0M) in Mar 2025.
- Notable investors include Impact Assets, South Park Commons, Hummingbird Ventures, Refactor Capital, Tao Capital Partners — 12 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 12 names
- ·Watchlist + deal alerts for Epana Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Epana Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Epana Bio
Developer of targeted therapeutic systems designed for autoimmune disease treatment. The company's platform integrates genomics analysis and artificial intelligence to identify and address the cellular origins of autoimmune disorders, supporting the discovery and development of precision medicines tailored to specific patient populations, enabling healthcare providers and patients in the autoimmune disease market to access therapies developed with a focused, data-driven approach aimed at improving treatment specificity and accelerating development timelines.
- Sector
- Healthcare
- HQ
- Berkeley, CA, United States
- Founded
- 2024
- Website
- epana.bio/
- Ownership
- Privately Held (backing)
Epana Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Epana Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Epana Bio in its N-PORT filings yet. We sweep new filings monthly.